Gandhar Oil Refinery (India) Limited — Investor Meet, 11-11-2024: Analysts/Institutional Investor Meet/Con. Call Updates

1. **Financial Performance**: In Q2 FY'25, Gandhar Oil Refinery reported a consolidated revenue of Rs 9,351 million, down from Rs 9,948 million in the previous quarter. For H1 FY'25, revenue totaled Rs 19,299 million, a decline from Rs 20,714 million year-over-year. Despite stable manufacturing volumes, gross margins fell to approximately Rs 8,500 per kilolitre due to declining crude prices and shipment delays. Q2 EBITDA was Rs 402 million, with profit after tax at Rs 181 million, down from Rs 326 million in the prior quarter, reflecting tighter margins and operational pressures.

2. **Future Outlook and Growth Drivers**: Management expressed a commitment to enhancing its international footprint, citing that around 40% of sales originate from overseas markets. The strategy includes diversifying product portfolios and targeting sectors like Personal Care and Healthcare. Despite current market hurdles, demand dynamics are expected to improve leading to better profitability in subsequent quarters.

3. **Order Book and Operational Updates**: Texol (UAE subsidiary) is currently utilizing 70-75% of its capacity, with expectations to hit 80-85% by year-end. As of now, Indian plants are operating at nearly full capacity (90-95%).

4. **Analyst Q&A Insights**:

- **Revenue and Profitability**: Analysts queried the drop in gross margins, with management clarifying that reduced crude prices and increased freight costs contributed significantly.

- **Market Position**: Analysts probed into the company's competitive landscape, with management indicating a steady market share and optimism about future orders from existing clients.

- **Operational Challenges**: Discussion on risks included shipping delays exacerbated by geopolitical issues, though improvements in the FMCG sector are anticipated.

- **Capex and Capital Allocation**: Discussion on IPO fund utilization revealed that most projects are near completion, with ongoing capex primarily for the Silvassa facility.

- **Strategic Priorities**: Management reinforced their focus on expanding production volume and entering new markets, emphasizing long-term growth.

5. **Market or Regulatory Updates**: There were no specific regulatory changes discussed that would directly impact operations, although updates regarding recent US FDA observations indicated minor non-monetary issues.

6. **Strategic Focus Areas**: A focus on market expansion and product diversification was noted. The management's tone suggested confidence in navigating current challenges while maintaining efficiency.

7. **Investor Insight**: Given the company’s solid international sales, ongoing operational adjustments, and management's optimistic outlook, the current financial health suggests a potential for growth. This aligns with a favorable investment outlook, suggesting a ‘buy’ stance, provided that macroeconomic conditions stabilize and operational efficiencies improve.